48 results about "Env Protein" patented technology

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

Antibodies and other molecules including an antigen binding region of an antibody that immunospecifically binds to a surface unit or a transmembrane unit of a Human endogenous retrovirus-K (HERV-K) Env protein are provided. The antibodies and other molecules typically include six complementarity determining regions (CDRs). In preferred forms the antibodies and other molecules immunospecifically bind to the amino acid sequence SEQ ID NO:223 and / or 224. Chimeric antigen receptors (CAR) formed using the provided antibodies are also provided, as are cell expressing the CAR. Methods of detecting HERV-K Env, and use thereof of various other methods such as diagnostic methods are also provided. Method of treatment for HERV-K Env protein-related diseases and disorders are also provided.

The invention relates to a Sebastes schlegeli endogenous retrovirus envelope protein Penv, a lentiviral vector and application thereof, and belongs to the field of genetic breeding of molecular biology, and the amino acid sequence of the envelope protein Penv is as shown in SEQ ID NO.1. The invention further provides an in-vitro assembly system, a transformant and a kit containing membrane fusion protein particles and lentiviral particles of the envelope protein Penv and application of the envelope protein Penv. VSVG protein is replaced with Penv protein from sclerobone fish, so that the transduction efficiency of the lentiviral particles to sclerobone fish cells is effectively improved, and the transduction efficiency of the lentiviral particles to the sclerobone fish cells is improved. And efficient gene delivery is realized. Meanwhile, as the endogenous Env protein, the Env protein overcomes the immunological rejection of a host to the exogenous Env protein, and also has the potential of in-vivo application.

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.

Implementations of an anti-tick vaccine composition may include one or more conserved tick proteins from a tick species; and one or more conserved outer membrane proteins of an endosymbiont of the tick species.

The invention particularly relates to a sebastes schlegeli endogenous retrovirus envelope protein percomORF, a lentiviral vector and application of the sebastes schlegeli endogenous retrovirus envelope protein percomORF and the lentiviral vector, and belongs to the field of genetic breeding of molecular biology, and the envelope protein percomORF has an amino acid sequence as shown in SEQ ID NO.1. The invention also covers a membrane fusion protein particle constructed based on the protein, a system for in-vitro assembly of lentivirus particles, a corresponding transformant and a matched kit. By replacing conventional VSVG protein with percomORF protein from sclerobone fish, the infection and transduction efficiency of lentivirus on sclerobone fish cells can be effectively enhanced, and more efficient gene delivery is realized. Besides, the protein belongs to host endogenous Env protein and is beneficial to avoiding immunological rejection caused by introduction of foreign protein, so that the protein has good potential in in-vivo gene delivery application.

Implementations of an anti-tick vaccine composition may include one or more conserved tick proteins from a tick species; and one or more conserved outer membrane proteins of an endosymbiont of the tick species.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The application discloses a liposome vaccine of Acinetobacter baumannii outer membrane protein and a preparation method and application thereof, and relates to the field of biological medicines. The application efficiently expresses the Acinetobacter baumannii outer membrane protein through a genetic engineering method, and obtains a liposome vaccine of Acinetobacter baumannii outer membrane protein by combining the obtained various outer membrane proteins as antigens with a lipid mixture and an adjuvant. It is verified that the vaccine can provide complete protection for mice attacked by a lethal dose of Acinetobacter baumannii. In the application, the outer membrane protein loaded in the liposome is re-folded in structure, the immunogenicity of the protein is enhanced, and the liposome can reduce the toxicity of the outer membrane protein. Omp38+BauA+FimA can be an effective antigen combination for preventing Acinetobacter baumannii infection. Pam2CSK4 as a TLR2 agonist has a strong auxiliary effect on the liposome vaccine of Acinetobacter baumannii, and can induce the activation of an innate immune response, thereby providing more comprehensive protection for a host.

The application belongs to the field of animal bacteriology and molecular biology technology, and relates to preparation of a hybridoma cell and application thereof. A monoclonal antibody is prepared through intracellular Lawsonia intracellularis outer membrane protein OmpA expressed by prokaryotes, and IFA, WB and blocking ELISA and other immunological detection methods for detecting or diagnosing Lawsonia intracellularis are established through the expressed intracellular Lawsonia intracellularis outer membrane protein OmpA and the prepared monoclonal antibody. The blocking ELISA for detecting serum antibodies of Lawsonia intracellularis can detect serum samples of suspected Lawsonia intracellularis infection from different species, and does not exist cross reaction with positive serum of common pig pathogens, has high sensitivity and specificity, is good in repeatability, and is suitable for high-throughput detection of serum samples.

According to the invention, dominant antigen epitopes of main outer membrane proteins OspA, OspB and OspC of borrelia burgdorferi are screened out, and a multi-epitope fusion vaccine containing the epitopes and application are constructed. The vaccine design not only improves the specificity and immunogenicity of the antigen. Compared with a traditional antigen epitope screening and construction strategy, the method has the advantages that the cycle is shortened, the cost is reduced, meanwhile, the limitations of many and complex antigens, large toxic and side effects and the like of a traditional vaccine are overcome, the operation process is simplified, the method is more suitable for large-scale epitope screening, popularization and application, and a new thought and strategy are provided for research and development of borrelia burgdorferi vaccines.

The application discloses a recombinant bacillus subtilis of surface display of a fusion protein of Edwardsiella tarda outer membrane protein OmpA and Vibrio cholerae enterotoxin CTB, a construction method and application. A homologous double cross recombinant of coding genes of OmpA and CTB is carried out into a genome of the bacillus subtilis 168 by taking the spore coat protein CotY as an anchor point, so that the recombinant bacillus subtilis capable of stably inheriting in the bacillus subtilis and displaying the Edwardsiella tarda outer membrane protein OmpA and the Vibrio cholerae enterotoxin CTB on a spore surface is obtained. After fish and mammals orally immunize the bacillus subtilis, the survival time and survival rate of the fish and mammals after infection of the Edwardsiella tarda are obviously improved. The recombinant bacillus subtilis is used as an oral vaccine type micro-ecological immunization preparation for preventing and treating the Edwardsiella tarda infection of the fish and mammals, so that the immunization procedure is obviously simplified, the immunization stress is reduced, the labor cost is saved, the effective concentration in the intestinal tract is ensured, and the specific immune response of the body is induced.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The invention relates to the field of bacterial membrane protein structures. More specifically, the invention relates to lipid nanodiscs compartmentalized by SlyB protein oligomers isolated from the outer membrane of Gram-negative bacteria. More specifically, the invention provides for a SlyB nanodisc structure wherein the SlyB-oligomer forms the membrane scaffold protein belt, which is surrounded by outer saccharolipid moieties anchored to the SlyB proteins, and which encloses a lipid bilayer nanodomain containing one or more phospholipid layers, wherein macromolecules such as (outer) membrane protein molecules may be captured and stabilized. More specifically, methods to produce and isolate chemically defined stable SlyB nanodisc particles are disclosed herein. Finally, the invention relates to the use of said SlyB nanodiscs as a self-adjuvanting vehicle, as part of an immunogenic composition, and provides for novel means for use in eliciting an immune response against macromolecules enclosed in said SlyB nanodiscs, or for use in a vaccine composition.

The invention discloses a genetically engineered bacterium for displaying laccase on the surface. The genetically engineered bacterium comprises a recombinant expression vector, the fusion protein expressed by the recombinant expression vector comprises a bacterial lipoprotein signal peptide, an outer membrane protein transmembrane anchoring structural domain and a laccase catalysis structural domain. The bacterial lipoprotein signal peptide and the outer membrane protein transmembrane anchoring structural domain are derived from Lpp-OmpA anchoring protein and are used for directionally transferring the laccase catalytic structural domain to periplasmic space and anchoring the laccase catalytic structural domain on the outer membrane surface of genetically engineered bacteria. The mycoderm catalyst disclosed by the invention has the characteristics of simplified preparation process, improved operation stability, reusability and the like, the treatment cost can be remarkably reduced, and the removal efficiency of endocrine disrupters in complex water bodies is improved.

Provided is the determination of the three-dimensional structure of Chlamydia major outer membrane protein and applications and uses thereof, including for vaccine development, drug development, and diagnostics.

Provided are a cra4S1 gene, an encoded cra4S1 protein, and a vaccine or drug containing the cra4S1 protein or a fragment thereof. A nucleotide sequence of the cra4S1 gene is represented by SEQ ID NO. 1. The vaccine combines the specific target of an outer membrane protein of Porphyromonas gingivalis and the antigen component of the bacterial conserved region, which has an immune prevention and protection effect on the body.

The invention provides an HIV-1 Env-derived immunogen that simultaneously engages more than one lineage of germline bNAbs specific for different neutralization target sites of the native HIV-1 Env trimer. In certain embodiments, the inventive immunogen comprises a chimeric Env, with binding sites drawn from more than one native Env proteins. These can be used both in the form of full-length / minimally truncated membrane-bound trimers (e.g., expressed from cDNA, mRNA or viral vectors, which also are provided by the present invention, as are cells comprising the immunogen) or, alternatively, in the form of soluble truncated trimers (e.g., SOSIP or IP trimers). Also provided are a pharmaceutical composition comprising the inventive immunogen, nucleic acids encoding the same, and / or cells comprising them, and a method of vaccinating a human patient against HIV using the inventive immunogen and composition.

The invention belongs to the technical field of biology, and provides a chlamydia trachomatis and gonococci double-target immunochromatography detection method which comprises the following steps: introducing a dibenzocyclooctyne group to the tail end of lipopolysaccharide of the chlamydia trachomatis, introducing a trans-cyclooctene group into outer membrane protein of gonococci, and detecting the chlamydia trachomatis and gonococci double-target immunochromatography. In the chromatographic detection process, the antibody can form two non-interfering detection channels with an anti-lipopolysaccharide antibody containing an azide group and an anti-outer membrane protein antibody containing a tetrazine group. Through the improvement, the problem that a high-concentration antigen occupies a binding site or interferes with a chromatography process due to nonspecificity can be avoided, and high specificity and high sensitivity of detection are ensured.

The present application relates to a kind of Sebastes schlegelii endogenous retrovirus envelope protein P_env, lentivirus vector and its application, belong to the genetic breeding field of molecular biology, the amino acid sequence of the envelope protein P_env is as shown in SEQ ID NO.1.The present application simultaneously provides the membrane fusion protein plasmid of containing the envelope protein P_env, the in vitro assembly system of lentivirus particle, transformant and kit, and the application of the envelope protein P_env, the P_env protein of the present application is replaced VSVG protein using hard fish source, will effectively improve the transduction efficiency of lentivirus particle to hard fish cell, realize efficient gene delivery.Meanwhile, as endogenous Env protein, overcome the immune rejection of host to exogenous Env protein, also have the potential of in-vivo application.

The invention relates to the technical field of genetic engineering, and provides recombinant escherichia coli with the surface displaying DM-Tfcut protein and a construction method and application of the recombinant escherichia coli. The recombinant escherichia coli is characterized in that DM-Tfcut protein is used as a template, outer membrane protein OmpA is used as anchoring protein, the DM-Tfcut protein and the outer membrane protein OmpA are fused and expressed on the surface of escherichia coli, recombinant escherichia coli with the surface displaying the DM-Tfcut protein is obtained, the amino acid sequence of the DM-Tfcut protein is shown as SEQ ID NO: 1, and the amino acid sequence of the outer membrane protein OmpA is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The DM-Tfcut protein is displayed on the surface of escherichia coli, the problems that free enzyme is poor in stability and high in preparation cost are solved, the DM-Tfcut protein is applied to whole-cell catalytic degradation of waste plastics and biosynthesis and utilization of degradation products, utilization of the waste plastics is achieved, the production process is optimized, and the production cost is reduced.

The invention relates to preparation of an antibacterial peptide inhibitor GLIP16 with good biocompatibility, stability and excellent antibacterial activity and application of the antibacterial peptide inhibitor GLIP16 in treatment of bacterial infection, and belongs to the field of medicine. The amino acid sequence of the antibacterial peptide inhibitor GLIP16 is C16H28N2O-His-Arg-Trp-Lys-Lys-Leu-Lys-Leu-Trp-Trp-Gly-Trp-Lys-Tyr-Lys-Phe-C6H12NO5 (abbreviated as C12H20N2O-WKKLLKWWLKKFKKLD-C6H12NO5), and the antibacterial peptide inhibitor GLIP16 is designed on the basis of a plurality of important biological characteristics (net positive charge, amphipathy and alpha-helical structure) of the antibacterial peptide and a key conserved sequence of an outer membrane protein beta signal, so that the antibacterial peptide inhibitor GLIP16 can be used for preparing the antibacterial peptide inhibitor GLIP16. Imidazolyl ionic liquid C16H29N2O2 and monosaccharide C6H13NO5 are respectively coupled to the N end and the C end of the N-terminal and the C-terminal of the N-terminal and the C-terminal of the N-terminal and the C-terminal. The invention provides a technical scheme for solid-phase synthesis of an antibacterial peptide inhibitor skeleton. The GLIP16 has excellent antibacterial activity, good in-vitro stability and good biocompatibility. An in-vivo antibacterial experiment shows that the designed antibacterial peptide inhibitor can play an excellent antibacterial role in a mouse infection model and is an antibiotic substitute with a good application prospect.

The invention discloses a Klebsiella pneumoniae antigen epitope chimeric protein as well as preparation and application thereof, and relates to the fields of genetic engineering technologies, vaccines and diagnostic reagents. Amino acid sequences of Klebsiella pneumoniae outer membrane proteins OMPA, OMPN and CusC are analyzed through a computer, two B cell epitopes, one HTL epitope and one CTL epitope are respectively screened from the three outer membrane proteins, a cholera toxin subunit B (CTB) is used as an internal adjuvant, an EAAAK joint is used for connecting the amino acid sequence of the CTB and the B cell epitope of the OMPA, the B cell epitope and the HTL epitope are connected through a GPGPG flexible joint, and the CTL epitope and the CusC epitope are connected through a GMPG flexible joint. CTL inner epitopes are connected through an AAY connector to form a chimeric protein with multiple antigen fragments connected in series. A codon preferred by a pronucleus is selected, and a full-length gene of the chimeric protein is chemically synthesized. The chimeric protein is expressed and purified by using a gene engineering technology, and the chimeric protein has 312 amino acids in total length. The expressed chimeric protein can be used for developing vaccines, antibodies or antigen detection reagents.

To provide virus-like particles (VLPs) for use in the prophylaxis and / or treatment of a disease derived from an endogenous retrovirus.SOLUTION: Provided is a virus-like particle (VLP), which is encoded by a nucleic acid molecule encoding an endogenous retrovirus (ERV) Gag protein and an ERV envelope (Env) protein, the Gag protein and the Env protein being linked via a self-cleavable peptide linker p2A, the nucleic acid molecule being an expression cassette.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of biology, and discloses an application of an outer membrane protein LI0688 of Lawsonia intracellularis in preparation of vaccines and diagnostic reagents, the outer membrane protein LI0688 is a target protein LI0688 after amino acid sequences of a transmembrane region and an intracellular region are removed or a recombinant protein fused by the target protein LI0688 and a His-MBP protein; the outer membrane protein LI0688 can realize soluble expression and purification, can be recognized by rabbit-derived LI positive serum and can induce high-level humoral immune response in a mouse body, and the titer of a specific IgG antibody can reach 1: 819200; the outer membrane protein LI0688 can be simultaneously used as a core antigen of a subunit vaccine and a key component of a high-specificity diagnostic reagent, so that the development cost is greatly reduced. Meanwhile, the invention also discloses a vaccine and a diagnostic kit based on the outer membrane protein LI0688.